Uri Galili has been a scientist in the area of immunology for 50 years. Forty years ago, he discovered, with co-workers, the natural anti-Gal antibody and the interaction of this antibody with its specific antigen, the alpha-gal epitope. He has been working on the basic science and translational and clinical research aspects of this antibody and the alpha-gal epitope, including harnessing anti-Gal for the in situ conversion of tumors into autologous anti-tumor vaccines, amplification of viral vaccines' immunogenicity, and induction of scar-free regeneration of wounds. Ten years ago, he retired from UMass Chan Medical School, where he worked as a professor in the Department of Surgery. Presently, he is an adjunct professor in the Department of Medicine at Rush University Medical Center in Chicago, researching methods for the induction of the regeneration of ischemic myocardium, post-myocardial infarction, and injured spinal cord by the interaction between anti-Gal and alpha-gal nanoparticles. Much of his work is detailed in the book: “The natural anti-Gal antibody as foe turned friend in medicine”, Academic Press/Elsevier, 2018.
Uri Galili has been a scientist in the area of immunology for 50 years. Forty years ago, he discovered, with co-workers, the natural anti-Gal antibody and the interaction of this antibody with its specific antigen, the alpha-gal epitope. He has been working on the basic science and translational and clinical research aspects of this antibody and the alpha-gal epitope, including harnessing anti-Gal for the in situ conversion of tumors into autologous anti-tumor vaccines, amplification of viral vaccines' immunogenicity, and induction of scar-free regeneration of wounds. Ten years ago, he retired from UMass Chan Medical School, where he worked as a professor in the Department of Surgery. Presently, he is an adjunct professor in the Department of Medicine at Rush University Medical Center in Chicago, researching methods for the induction of the regeneration of ischemic myocardium, post-myocardial infarction, and injured spinal cord by the interaction between anti-Gal and alpha-gal nanoparticles. Much of his work is detailed in the book: “The natural anti-Gal antibody as foe turned friend in medicine”, Academic Press/Elsevier, 2018.